When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CALA - Dosing underway in Calithera Bio's early-stage CB-280 trial for cystic fibrosis
Calithera Biosciences Inc.
Calithera Biosciences (NASDAQ:CALA) has dosed the first patients in its Phase 1b clinical trial of the arginase inhibitor CB-280 in adult patients with cystic fibrosis (CF) and chronic airway infection.
More news on: Calithera Biosciences, Inc., Healthcare stocks news,